Magnetic Resonance Relaxometry in Quantitative Imaging of Brain Gliomas: A Literature Review

Overview

Journal Neuroradiol J

Publisher Sage Publications

Specialties Neurology
Radiology

Date 2023 May 3

PMID 37133228

Authors

Ivan V Chekhonin

Ouri Cohen

Ricardo Otazo

Robert J Young

Andrei I Holodny

Igor N Pronin

Affiliations

Soon will be listed here.

Abstract

Magnetic resonance (MR) relaxometry is a quantitative imaging method that measures tissue relaxation properties. This review discusses the state of the art of clinical proton MR relaxometry for glial brain tumors. Current MR relaxometry technology also includes MR fingerprinting and synthetic MRI, which solve the inefficiencies and challenges of earlier techniques. Despite mixed results regarding its capability for brain tumor differential diagnosis, there is growing evidence that MR relaxometry can differentiate between gliomas and metastases and between glioma grades. Studies of the peritumoral zones have demonstrated their heterogeneity and possible directions of tumor infiltration. In addition, relaxometry offers T2* mapping that can define areas of tissue hypoxia not discriminated by perfusion assessment. Studies of tumor therapy response have demonstrated an association between survival and progression terms and dynamics of native and contrast-enhanced tumor relaxometric profiles. In conclusion, MR relaxometry is a promising technique for glial tumor diagnosis, particularly in association with neuropathological studies and other imaging techniques.

Citing Articles

Synthetic MR: Clinical applications in neuroradiology.

Sharma S, Nayak A, Thomas B, Kesavadas C Neuroradiology. 2025; .

PMID: 39888426 DOI: 10.1007/s00234-025-03547-8.

A Histopathologic Correlation Study Evaluating Glymphatic Function in Brain Tumors by Multiparametric MRI.

Gao M, Liu Z, Zang H, Wu X, Yan Y, Lin H Clin Cancer Res. 2024; 30(21):4876-4886.

PMID: 38848042 PMC: 11528195. DOI: 10.1158/1078-0432.CCR-24-0150.

Advancements in Image-Based Models for High-Grade Gliomas Might Be Accelerated.

Frosina G Cancers (Basel). 2024; 16(8).

PMID: 38672647 PMC: 11048778. DOI: 10.3390/cancers16081566.

Novel advanced imaging techniques for cerebral oedema.

Pham J, Ng F Front Neurol. 2024; 15:1321424.

PMID: 38356883 PMC: 10865379. DOI: 10.3389/fneur.2024.1321424.

References

Patel S, Poisson L, Brat D, Zhou Y, Cooper L, Snuderl M . T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project. Clin Cancer Res. 2017; 23(20):6078-6085. DOI: 10.1158/1078-0432.CCR-17-0560. View

Deoni S . Quantitative relaxometry of the brain. Top Magn Reson Imaging. 2011; 21(2):101-13. PMC: 3613135. DOI: 10.1097/RMR.0b013e31821e56d8. View

Chekhonin I, Batalov A, Zakharova N, Pogosbekyan E, Nikitin P, Bykanov A . [Magnetic resonance relaxometry in high-grade glioma subregion assessment - neuroimaging and morphological correlates]. Zh Vopr Neirokhir Im N N Burdenko. 2021; 85(4):41-48. DOI: 10.17116/neiro20218504141. View

Broen M, Smits M, Wijnenga M, Dubbink H, Anten M, Schijns O . The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol. 2018; 20(10):1393-1399. PMC: 6120363. DOI: 10.1093/neuonc/noy048. View

Villanueva-Meyer J, Barajas Jr R, Mabray M, Chen W, Shankaranarayanan A, Koon P . Differentiation of brain tumor-related edema based on 3D T1rho imaging. Eur J Radiol. 2017; 91:88-92. PMC: 5563444. DOI: 10.1016/j.ejrad.2017.03.022. View

Lescher S, Jurcoane A, Veit A, Bahr O, Deichmann R, Hattingen E . Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI. Neuroradiology. 2014; 57(1):11-20. DOI: 10.1007/s00234-014-1445-9. View

Hagiwara A, Warntjes M, Hori M, Andica C, Nakazawa M, Kumamaru K . SyMRI of the Brain: Rapid Quantification of Relaxation Rates and Proton Density, With Synthetic MRI, Automatic Brain Segmentation, and Myelin Measurement. Invest Radiol. 2017; 52(10):647-657. PMC: 5596834. DOI: 10.1097/RLI.0000000000000365. View

Cheng H, Stikov N, Ghugre N, Wright G . Practical medical applications of quantitative MR relaxometry. J Magn Reson Imaging. 2012; 36(4):805-24. DOI: 10.1002/jmri.23718. View

Ellingson B, Chung C, Pope W, Boxerman J, Kaufmann T . Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol. 2017; 134(3):495-504. PMC: 7893814. DOI: 10.1007/s11060-017-2375-2. View

10.

Zikou A, Sioka C, Alexiou G, Fotopoulos A, Voulgaris S, Argyropoulou M . Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. Contrast Media Mol Imaging. 2019; 2018:6828396. PMC: 6305027. DOI: 10.1155/2018/6828396. View

11.

Mehta B, Coppo S, Frances McGivney D, Ian Hamilton J, Chen Y, Jiang Y . Magnetic resonance fingerprinting: a technical review. Magn Reson Med. 2018; 81(1):25-46. DOI: 10.1002/mrm.27403. View

12.

Cohen O, Zhu B, Rosen M . MR fingerprinting Deep RecOnstruction NEtwork (DRONE). Magn Reson Med. 2018; 80(3):885-894. PMC: 5980718. DOI: 10.1002/mrm.27198. View

13.

Warntjes J, Dahlqvist Leinhard O, West J, Lundberg P . Rapid magnetic resonance quantification on the brain: Optimization for clinical usage. Magn Reson Med. 2008; 60(2):320-9. DOI: 10.1002/mrm.21635. View

14.

Ellingson B, Lai A, Nguyen H, Nghiemphu P, Pope W, Cloughesy T . Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI. Clin Cancer Res. 2015; 21(19):4373-83. PMC: 4592379. DOI: 10.1158/1078-0432.CCR-14-2862. View

15.

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

16.

Hamilton-Craig C, Strudwick M, Galloway G . Mapping for Myocardial Fibrosis by Cardiac Magnetic Resonance Relaxometry-A Comprehensive Technical Review. Front Cardiovasc Med. 2017; 3:49. PMC: 5352660. DOI: 10.3389/fcvm.2016.00049. View

17.

Piper R, Mikhael S, Wardlaw J, Laidlaw D, Whittle I, Bastin M . Imaging signatures of meningioma and low-grade glioma: a diffusion tensor, magnetization transfer and quantitative longitudinal relaxation time MRI study. Magn Reson Imaging. 2015; 34(4):596-602. PMC: 4801649. DOI: 10.1016/j.mri.2015.12.006. View

18.

Ni W, Christen T, Zun Z, Zaharchuk G . Comparison of R2' measurement methods in the normal brain at 3 Tesla. Magn Reson Med. 2014; 73(3):1228-36. PMC: 4308575. DOI: 10.1002/mrm.25232. View

19.

Brady T, Buonanno F, Pykett I, NEW P, Davis K, Pohost G . Preliminary clinical results of proton (1H) imaging of cranial neoplasms: in vivo measurements of T1 and mobile proton density. AJNR Am J Neuroradiol. 1983; 4(3):225-8. PMC: 8334929. View

20.

Pirkl C, Nunez-Gonzalez L, Kofler F, Endt S, Grundl L, Golbabaee M . Accelerated 3D whole-brain T1, T2, and proton density mapping: feasibility for clinical glioma MR imaging. Neuroradiology. 2021; 63(11):1831-1851. PMC: 8528802. DOI: 10.1007/s00234-021-02703-0. View